Physician profile
Ashmead Ali
NPI 1215009113
$602.99
in general payments reported to CMS, 2019-2025
13 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $96.88 · 2022: $30.23 · 2023: $32.27 · 2024: $122 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.98 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.34 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.88 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $96.81 | 2025 | Ozempic, Wegovy |
| Eisai INC. | $35.10 | 2020-2021 | |
| Amgen INC. | $20.91 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $20.59 | 2021 | |
| Verona Pharma, INC. | $18.83 | 2025 | Ohtuvayre |
| Dexcom, INC. | $17.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2023 | Farxiga |
| Nestle Healthcare Nutrition INC. | $15.22 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.67 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.95 | 2021 | |
| Glaxosmithkline, LLC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashmead Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.